Stock Track | Viking Therapeutics Soars 20.41% Pre-market on Positive Outlook for Obesity Drug Market

Stock Track12-20 19:44

Viking Therapeutics (VKTX) stock surged 20.41% in the pre-market trading session on Friday, outperforming the broader market. This significant pre-market upswing came after Novo Nordisk's obesity drug, CagriSema, failed to meet expectations in a late-stage trial, potentially benefiting rival companies in the weight-loss drug market.

Novo Nordisk announced that CagriSema helped overweight patients reduce their weight by 22.7%, lower than the 25% weight loss the company had anticipated. This underwhelming performance raised concerns about Novo Nordisk's competitiveness in the lucrative obesity drug market, leading investors to shift their focus to alternative players like Viking Therapeutics.

With Novo Nordisk's setback, Viking Therapeutics' prospects in the obesity drug space have become more appealing to investors. As a company focused on developing innovative therapies for metabolic disorders, including obesity, Viking Therapeutics could potentially benefit from the increased competition and demand for effective weight-loss treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196040634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196040634","market":"hk","top_or_hot":-1,"title":"Stock Track | Viking Therapeutics Soars 20.41% Pre-market on Positive Outlook for Obesity Drug Market","media":"Stock Track","content":"<p>Viking Therapeutics (VKTX) stock surged 20.41% in the pre-market trading session on Friday, outperforming the broader market. This significant pre-market upswing came after Novo Nordisk's obesity drug, CagriSema, failed to meet expectations in a late-stage trial, potentially benefiting rival companies in the weight-loss drug market.</p>\n\n<p>Novo Nordisk announced that CagriSema helped overweight patients reduce their weight by 22.7%, lower than the 25% weight loss the company had anticipated. This underwhelming performance raised concerns about Novo Nordisk's competitiveness in the lucrative obesity drug market, leading investors to shift their focus to alternative players like Viking Therapeutics.</p>\n\n<p>With Novo Nordisk's setback, Viking Therapeutics' prospects in the obesity drug space have become more appealing to investors. As a company focused on developing innovative therapies for metabolic disorders, including obesity, Viking Therapeutics could potentially benefit from the increased competition and demand for effective weight-loss treatments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Viking Therapeutics Soars 20.41% Pre-market on Positive Outlook for Obesity Drug Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Viking Therapeutics Soars 20.41% Pre-market on Positive Outlook for Obesity Drug Market\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-20 19:44 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viking Therapeutics (VKTX) stock surged 20.41% in the pre-market trading session on Friday, outperforming the broader market. This significant pre-market upswing came after Novo Nordisk's obesity drug...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VKTX","symbol_name":"Viking Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1196040634","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196040634","pubTimestamp":1734695066,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Viking Therapeutics  stock surged 20.41% in the pre-market trading session on Friday, outperforming the broader market. This significant pre-market upswing came after Novo Nordisk's obesity drug, CagriSema, failed to meet expectations in a late-stage trial, potentially benefiting rival companies in the weight-loss drug market.Novo Nordisk announced that CagriSema helped overweight patients reduce their weight by 22.7%, lower than the 25% weight loss the company had anticipated. This underwhelmin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VKTX":"Viking Therapeutics, Inc."},"translate_title":"由于肥胖药物市场前景乐观，Viking Therapeutics盘前飙升20.41%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1},"content_text":"Viking Therapeutics (VKTX) stock surged 20.41% in the pre-market trading session on Friday, outperforming the broader market. This significant pre-market upswing came after Novo Nordisk's obesity drug, CagriSema, failed to meet expectations in a late-stage trial, potentially benefiting rival companies in the weight-loss drug market.\nNovo Nordisk announced that CagriSema helped overweight patients reduce their weight by 22.7%, lower than the 25% weight loss the company had anticipated. This underwhelming performance raised concerns about Novo Nordisk's competitiveness in the lucrative obesity drug market, leading investors to shift their focus to alternative players like Viking Therapeutics.\nWith Novo Nordisk's setback, Viking Therapeutics' prospects in the obesity drug space have become more appealing to investors. As a company focused on developing innovative therapies for metabolic disorders, including obesity, Viking Therapeutics could potentially benefit from the increased competition and demand for effective weight-loss treatments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196040634"}